Letter to the editor re: molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Alexander Sauter & Armin Kolb & Martin Soekler & Matthias Reimold & Nina Schwenzer & Christina Pfannenberg & Claus Claussen & Bernd Pichler & Marius H
- چاپ و سال / کشور: 2011
Description
Recently, Schiepers et al. [1] have illuminated the emerging field of MR/PET imaging and its expected great potential. We are in agreement with the authors that a lower radiation exposure, a reliable image registration, constant physiological conditions, multifunctional imaging possibilities and a higher patient through-put are the major advantages of simultaneous MR/PET imaging. To illustrate simultaneous MR/PET imaging in the field of oncology we have examined a 70-year old patient with histologically confirmed diffuse large B-cell lymphoma in the left tibia. Before therapy onset with R-CHOP a baseline whole-body [18F]-FDG-PET/CT (Biograph 16; Siemens Healthcare, Germany) acquiring 9 bed positions (3 min/bed) (Fig. 1a-c) and a subsequent (approx. 2 h after tracer injection) MR/PET (30 min acquisition time) (Fig. 2a-c) of the tibia were performed. The MR/PET system consists of an MRI-compatible PET system (BrainPET; Siemens Healthcare, USA) based on avalanche photo diodes (APDs) and LSO scintillation crystals that slip-fits into a modified 3 T whole-body MRI system (Magnetom Tim Trio; Siemens Healthcare, Germany). The sensitivity of the MR/PET is 7.4%, approximately three times higher than the PET/CT. Additionally, the spatial resolution in the center of the FOV is <2.5 mm compared to 4.5 mm in the PET/CT. For the BrainPET acquisition, the attenuation correction was calculated using tissue specific thresholds on T1- weighted MR images.
Eur Radiol (2011) 21:1709–1712 DOI 10.1007/s00330-011-2096-4 Received: 11 January 2011 / Revised: 31 January 2011 / Accepted: 14 February 2011 / Published online: 5 March 2011
